TWiV 1112: Clinical update with Dr. Daniel Griffin

May 11, 2024

In his weekly clinical update, Dr. Griffin deep dives into infections of dairy cattle with high pathogenic influenza H5N1, how long virus has been circulating and if known anti-influenza antivirals can reduce secondary attack rates, before reviewing the recent statistics on SARS-CoV-2 infection, the guidelines for spring administration of COVID vaccines boosters, whether COVID booster takes associates with long COVID prevalence, discusses the emergency use application of a pre-exposure prophylactic, if administration of oral antiviral therapies can prevent the onset of post-acute sequelae following SARS-CoV-2 infection, continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, compares and contrasts the cognitive profile in multiple sclerosis and post-COVID, exercise intolerance following SARS-CoV-2 infection and the epidemiology of the pandemic in a Kenyan refugee camp. For more information about this body of work, listen to TWiV 1088.

Click arrow to play
Download TWiV 1112 (36 MB .mp3, 47 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Technical reports on high path avian influenza (CDC)

High path cow influenza H5N1 clade (Emerging Infectious Diseases)

Cow flu flying around for 4 months (CNN)

Interstate commerce: high path avian influenza in dairy cattle (bioRxiv)

Oseltamivir and baloxavir marboxil treatment for influenza in household index cases (Influenza and other respiratory viruses)

COVID-19 national trend (CDC)

COVID-19 deaths (CDC)

Spring vaccine advice (CIDRAP)

Older adult spring booster available (CDC)

Advisory committee for immunization practices slides (CDC)

Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)

EUA for pemgarda (FDA)

CDC Quarantine guidelines (CDC)

NIH COVID-19 treatment guidelines (NIH)

Infectious Disease Society guidelines for treatment and management (IDSociety)

Overuse ofantibiotics for COVID-19: a viral disease (European Soc Clin Micro Inf Dis)

Molnupiravir safety and efficacy (JMV)

Convalescent plasma recommendation for immunocompromised (IDSociety)

Outpatient treatment with concomitant vaccine-boosted convalescent plasma (mBio)

Updated respiratory virus guidances (CDC)

What do when your heathcare provider is infected with SARS-CoV-2 (CDC)

Managing healthcare staffing shortages (CDC)

Antiviral effect of metformin on SARS-CoV-2 viral load (CID)

Nirmatrelvir-ritonavir to prevent post-acute sequelae and mortality in SARS-CoV-2 hospitalized patients (Lancet Infectious Diseases)

Oral antivirals for acute and post-acute sequelae from SARS-CoV-2 infection (Lancet Infectious Diseases)

Nirmatrelvir-ritonavir for prevention of COVID-19 related hospitalization (American Journal of Therapeutics)

Nirmatrelvir-ritonavir effectiveness (American Therapeutics)

Steroids,dexamethasone at the right time (OFID)

Anticoagulation guidelines (

Long COVID evidence based review TWiV shout out (TWiV 1088)

Cognitive profile in multiple sclerosis and post-COVID (Scientific reports)

Exercise intolerance in long COVID (American Journal of Medicine)

Epidemiology of SARS-CoV-2 in the Kakuma refugee camp, Kenya (Emergining Infectious Diseases)

Rohingya refugees (USA for UNHCR)

Contribute to our Floating Doctors fundraiser

Letters read on TWiV 1112

Dr. Griffin’s COVID treatment summary (pdf)

Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

The post TWiV 1112: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.

Leave a Reply

Your email address will not be published. Required fields are marked *